AR073573A1 - Metodos para utilizar composiciones de aminopiridina de liberacion sostenida - Google Patents

Metodos para utilizar composiciones de aminopiridina de liberacion sostenida

Info

Publication number
AR073573A1
AR073573A1 ARP090103479A ARP090103479A AR073573A1 AR 073573 A1 AR073573 A1 AR 073573A1 AR P090103479 A ARP090103479 A AR P090103479A AR P090103479 A ARP090103479 A AR P090103479A AR 073573 A1 AR073573 A1 AR 073573A1
Authority
AR
Argentina
Prior art keywords
methods
sustained release
compositions
aminopiridine
subject
Prior art date
Application number
ARP090103479A
Other languages
English (en)
Inventor
Andrew Blight
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AR073573A1 publication Critical patent/AR073573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se dan a conocer en este documento métodos y composiciones relacionadas al uso de aminopiridinas, tal corno fampridina, para mejorar los deterioros de pacientes con una afeccion de desmielinizacion, tal corno MS. Reivindicacion 4: Un método para tratar esclerosis multiple en un sujeto, caracterizado porque comprende administrar al sujeto un inmunomodulador; y administrar al sujeto una composicion de liberacion sostenida que comprende 10 miligramos de 4-aminopiridina dos veces al día. Reivindicacion 5: El método de conformidad con la reivindicacion 4, caracterizado porque el inmunomodulador se selecciona de interferones, natalizumab, acetato de glatirámero y combinaciones de los mismos.
ARP090103479A 2008-09-10 2009-09-10 Metodos para utilizar composiciones de aminopiridina de liberacion sostenida AR073573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
AR073573A1 true AR073573A1 (es) 2010-11-17

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103479A AR073573A1 (es) 2008-09-10 2009-09-10 Metodos para utilizar composiciones de aminopiridina de liberacion sostenida

Country Status (15)

Country Link
US (3) US20100061935A1 (es)
EP (1) EP2343976A4 (es)
JP (1) JP2012502103A (es)
CN (1) CN101827522A (es)
AR (1) AR073573A1 (es)
AU (1) AU2009291781A1 (es)
BR (1) BRPI0903914A2 (es)
CA (1) CA2736381A1 (es)
CL (1) CL2009001841A1 (es)
PA (1) PA8841801A1 (es)
PE (1) PE20100264A1 (es)
RU (1) RU2011113762A (es)
TW (1) TW201010703A (es)
UY (1) UY32109A (es)
WO (1) WO2010030755A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP3381455A1 (en) * 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (es) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US20070037848A1 (en) * 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
EP1651169A4 (en) * 2003-08-01 2008-02-27 Medarex Inc POLYTHERAPIES FOR MULTIPLE SCLEROSIS
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20060276537A1 (en) * 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
WO2007035958A2 (en) * 2005-09-23 2007-03-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment

Also Published As

Publication number Publication date
BRPI0903914A2 (pt) 2015-07-21
AU2009291781A1 (en) 2010-03-18
US20100061935A1 (en) 2010-03-11
UY32109A (es) 2010-04-30
PE20100264A1 (es) 2010-04-28
EP2343976A4 (en) 2011-12-14
TW201010703A (en) 2010-03-16
CL2009001841A1 (es) 2011-02-18
US20130330277A1 (en) 2013-12-12
RU2011113762A (ru) 2012-10-20
CN101827522A (zh) 2010-09-08
CA2736381A1 (en) 2010-03-18
JP2012502103A (ja) 2012-01-26
US20130072527A1 (en) 2013-03-21
PA8841801A1 (es) 2010-06-28
EP2343976A1 (en) 2011-07-20
WO2010030755A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
AR073573A1 (es) Metodos para utilizar composiciones de aminopiridina de liberacion sostenida
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
UA100840C2 (ru) Композиция для лечения вирусного гепатита
BRPI0719008A2 (pt) Inibidores de vírus da hepatite c
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
MX2012008221A (es) Inhibidores de virus flaviviridae.
ATE485304T1 (de) Muteine von tearlipocalin und verfahren zu deren gewinnung
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
MY160130A (en) Hepatitis c virus inhibitors
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
AR077765A1 (es) Inhibidores de los virus flaviviridae
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
BR112013002729A2 (pt) inibidores de vírus de hepatite c
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
SE0301882D0 (sv) New use I
RS53598B1 (en) TOPICAL PREPARATIONS FOR THE CONSERVATION OR RE-ESTABLISHMENT OF MALFIN INTEGRITY

Legal Events

Date Code Title Description
FA Abandonment or withdrawal